Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Paper of the day - Combined heart drugs risk

Combined ARB and ACE inhibitor treatment for heart failure markedly increases adverse effects compared with ACE inhibitor treatment alone, a meta-analysis has concluded.

US researchers looked at four studies involving 17,337 patients with an average of 25 months follow-up.

Patients with chronic heart failure taking an ARB/ACE inhibitor combination were 38% more likely to discontinue treatment due to adverse effects.

They also had double the risk of worsening renal function; almost five times the risk of hyperkalemia and a 50 per cent increased risk of symptomatic hypotension.

Arch Intern Med 2007; 167: 1930-1936

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say